



**Financial Results for FYE/ Mar.2007
&
Business Plan for FYE/Mar.2008**

Terumo Corporation

Sales and profits enjoyed double-digit growth


(Unit: billion yen)

	FYE/Mar. 2006	FYE/Mar. 2007	Rate of change
Net Sales	247.0	276.4	11.9%
Gross Profit (%)	135.7 (54.9%)	153.3 (55.5%)	13.0%
S.G.A Expenses (%)	87.4 (35.4%)	94.9 (34.3%)	8.5%
Operating Income (%)	48.3 (19.5%)	58.5 (21.2%)	21.1%
Ordinary Income (%)	48.9 (19.8%)	58.0 (21.0%)	18.6%
Net Income (%)	32.5	37.2	14.7%

Average exchange rate	US\$	113 yen	117 yen	3.2% yen depreciation
	EUR	138 yen	150 yen	8.8% yen depreciation

Net Sales (by Product group)

(Unit: billion yen)




Consolidated total: 11.9% growth

- CV and vascular grafts
(Growth rate: 14.5%)
- Interventional products
(Growth rate: 30.0%)
- Home health care products
(Growth rate: 1.9%)
- General hospital products
(Growth rate: 6.4%)

Net Sales (by Region)

(Unit: billion yen)



Outside Japan sales ratio (%)

40% → 45%

Consolidated Net Sales
Growth rate 11.9% (9.5%)


Asia & Others 17.5% (11.7%)

Americas 36.6% (33.3%)

Europe 22.2% (13.3%)

Outside Japan 26.9% (20.9%)


Japan 2.1%



Excluding impact of foreign exchange

Details of S.G.A Expenses

(Unit: billion yen)



S.G.A Expenses rate
 35.4% 34.3%

▲ 1.1pt


*Excepted MicroVention one-time R&D expense



Toward Achieving the Goals of the Mid-term Plan, STePUP2007


Cardiac & Vascular products driving growth, with general hospital products sales steady

(Unit: billion yen)



Outside Japan business greatly expanded while Japan sales showed growth despite unfavorable conditions


(Unit: billion yen)



Growing products 1) I.V. solution sets

◆ I.V. solution sets for risk management increased sales

(Unit: billion yen)




I.V. solution sales transition

□ Ordinary □ Risk management


Growing products 2) Pre-filled syringes

◆ Sales of Pre-filled syringes in Japan

(Unit: billion yen)




◆ Penetration of prefilled products



Generic I.V. solution "Soldem" enjoying growth

(Unit: Ten thousand bottles)




Quantity — Share in Japan

(IMS data)


Overseas sales by region

(Unit: billion yen)




European market

- ◆ Continuous high sales growth in interventional products
- ◆ Presence of vascular grafts (of Vascutek) playing a critical role




Interventional business in Europe

◆ Grown in all product groups



Vascutek Strategy

◆ Vascutek's sales transition



Stent graft (Anaconda)

- Minimally invasive therapy
in the surgical domain




Vascular grafts (BioValsalva)

- Composite of biological valve
and synthetic vascular graft
- ※ Introducing the technology from Kohler Chemie
(Kohler's biological valve business acquired in Mar.2007)



US market


- ◆ Drastic growth of intervention product sales (M&A+shift to direct sales)
- ◆ Planning business growth in cardiac surgery domain



Launching PTCA guidewire, “Runthrough NS”

◆ Taking advantage of No.1 position
in guide wire for angiographies in the US

Sales & share of PTCA guidewire in Japan



New products in cardiopulmonary systems

◆ Endoscopic Vein Harvesting system, "VirtuoSaph"

- Jointly developed with Olympus and launched in the US in 2005


- Sales in the US: about 900 million yen in FYE/Mar. 2007

⇒ Expected sales of 2.3 billion yen in FYE/Mar. 2008

"VirtuoSaph"




Scar from conventional
vein harvesting operation



Scar from VirtuoSaph

Asian market

- ◆ Business properties similar to those of Japan
- ◆ Market expanding thanks to improving medical standards



Expanding the supply of general hospital medical devices

◆ Buildings of plant in Vietnam to be completed in May

- Production facilities to be move into the plant after completion of building construction
- Mainly produces highly functional products contributing to medical safety



Left Ventricular Assist System "DuraHeart[®]"

Approved CE mark February 2007

◆ Europe

- Launch scheduled in the first half of this fiscal year
- To be marketed by Vascutek Ltd.

◆ Japan

- The Ministry of Health, Labour and Welfare studying early approval

◆ US

- Application for clinical tests scheduled by the end of this fiscal year



"DuraHeart[®]"


Drug Eluting Stent "Nobori"[®]

◆ Europe

- Applied for the CE mark and awaiting the results
- Sales in Europe and Asia to be started after CE marked

◆ Japan

- In the process of preparing for clinical tests



Drug Eluting Stent
"Nobori"[®]

Striving to achieve the double-digit profit growth in FYE/Mar. 2008

(Unit: billion yen)

	FYE/Mar. 2007	FYE/Mar. 2008 (forecast)	Increase rate	
Net Sales	276.4	300.0	9%	
Operating Income (%)	58.5 (21.2%)	64.0 (21.3%)	10%	(13%)
Ordinary Income (%)	58.0 (21.0%)	64.0 (21.3%)	10%	(13%)
Net Income (%)	37.2	41.2	11%	(14%)

Exchange rate for
the year

US\$ 117 yen
EUR 150 yen

US\$ 115 yen (1.7% yen appreciation)
EUR 150 yen

Exclude impact of tax reforms
– F.A. depreciation

Striving to achieve the double-digit profit growth in FYE/Mar. 2008

(Unit: billion yen)

	FYE/Mar. 2007	FYE/Mar. 2008 (forecast)	Increase rate	
Net Sales	276.4	300.0	9%	
Operating Income (%)	58.5 (21.2%)	64.0 (21.3%)	10%	(13%)
Ordinary Income (%)	58.0 (21.0%)	64.0 (21.3%)	10%	(13%)
Net Income (%)	37.2	41.2	11%	(14%)

Exchange rate for
the year

US\$ 117 yen
EUR 150 yen

US\$ 115 yen (1.7% yen appreciation)
EUR 150 yen

Exclude impact of tax reforms
– F.A. depreciation



IR Contact

TERUMO Corporation

Corporate Communication (IR) Dept.

E-mail: CCD@terumo.co.jp

This document contains forward-looking statements that reflect management's current views with respect to certain future events and financial performance. Actual results may differ materially from those projected or implied in the forward-looking statements and from historical trends. Furthermore, certain forward-looking statements are based upon assumptions of future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those projected or implied in any forward-looking statements include, but are not limited to, changes in overall economic conditions, fluctuations of foreign exchange rates, and intensifying price competition in the markets for our products.